Market News & Trends
Bormioli Pharma Completes Acquisition of Remy & Geiser
Bormioli Pharma S.p.A. recently announced the successful completion of its acquisition of Remy & Geiser GmbH (R&G), a German company active in the business of…
Streamlining Drug Development Processes Through the Accenture INTIENT Clinical Platform
To facilitate the demand for this new world order, we’ve unveiled the Accenture INTIENT Clinical platform. It helps companies run faster clinical trials with better transparency and….
Gerresheimer Opens US Glass Innovation & Technology Center
Gerresheimer is driving innovation in pharmaceutical glass, primary packaging glass products, technologies, and digitized processes. In the future, highly qualified engineers at the recently opened Gx Glass Innovation and Technology Center will develop….
Cue Biopharma Doses First Patient in Clinical Trial
Cue Biopharma, Inc. recently announced it dosed the first patient in a Phase 1 clinical trial of CUE-101 at Washington University, Alvin J. Siteman Cancer Center, St. Louis, Missouri for the treatment of….
VivaLNK Delivers Continuomics Using Wearable Medical Sensors
VivaLNK, a leading provider of connected healthcare solutions, is improving clinical trials with continuomics by using wearable medical sensors for….
Cabaletta Bio Receives IND Clearance From FDA to Initiate First Clinical Trial
Cabaletta Bio, Inc. recently announced it has received clearance of its IND application from the US FDA to initiate a first-in-human clinical trial of…..
Thermo Fisher Scientific Expands API Manufacturing Capabilities
Thermo Fisher Scientific recently announced the expansion of its API manufacturing capabilities following the completion of its previously announced acquisition of an active pharmaceutical ingredient…
Ocugen & CanSinoBIO Enter Strategic Co-Development & Manufacturing Partnership
Ocugen, Inc. has recently entered into a strategic partnership with CanSino Biologics on Ocugen’s gene therapy pipeline product candidates for inherited retinal diseases, which are…
Novel Silica Delivery System Enters Final Preclinical Development Stage
N4 Pharma Plc recently announced results from the company’s latest research study into its novel silica nanoparticle for cancer treatments and vaccines, Nuvec. The work,…
TrakCel Announces Strategic Partnership With WuXi AppTec Advanced Therapies
TrakCel and WuXi AppTec Advanced Therapies recently announced a collaborative agreement designed to accelerate the seamless delivery of advanced therapy treatments to bring an end-to-end…
AGTC & Otonomy Announce Strategic Collaboration to Develop & Commercialize Gene Therapy
Applied Genetic Technologies Corporation and Otonomy, Inc. recently announced they have entered into a strategic collaboration to co-develop and co-commercialize an AAV-based gene therapy to…
North America Leads in Number of Strategic Pharma Partnerships
From 2014 to the first half (H1) of 2019, there were more than 1,300 separate strategic partnerships and 1,000 licensing agreements made in the global…
Entera Bio Reports Positive Results from a Phase 2 PK/PD Study of Oral PTH
Entera Bio Ltd. recently announced the presentation of positive results from its pharmacokinetic (PK) and pharmacodynamic (PD) study in patients with hypoparathyroidism treated with its…
Dance Biopharm Presents Phase 2 Clinical Data Highlighting Rapid Effects of Inhaled Human Insulin
Dance Biopharm Holdings, Inc., recently presented data from its Phase 2 clinical study of Dance 501, a novel gentle mist formulation of human insulin administered with its….
Immutep to Receive Milestone Payment From GSK
Immutep Limited recently announced it will receive a milestone payment from GSK of $5.02 million related to the first patient being dosed in…..
Atlas Nanotech Announces Successful Development of First-Ever OTC Nanotechnology Vitamin A
Costas Inc. DBA Atlas Nanotech adds another unique nanotechnology medical product to its portfolio. Recently, CEO Dr. Julio Riestra announced the completion of development of…
Mustang Bio Announces Phase 1 Clinical Trial
Mustang Bio, Inc. recently announced that City of Hope, a world-renowned independent cancer research and treatment center, has opened and is beginning to treat its…
Novo Nordisk & Emisphere Announce Development Update
Novo Nordisk recently announced the Federal Food and Drug Administration (FDA) has approved Rybelsus, a semaglutide tablet, for the treatment of adults with type 2…
Minerva Neurosciences & Catalent Enter Commercial Supply Agreement
Minerva Neurosciences, Inc. and Catalent recently announced they have entered into a long-term commercial supply agreement for Roluperidone (MIN-101), an investigational compound under development by…
Aptevo Therapeutics Introduces New Adaptir Bispecific Antibody Candidate
Aptevo Therapeutics Inc. recently introduced a new immuno-oncology candidate, APVO603, built on Aptevo’s proprietary ADAPTIR bispecific antibody platform. Jane Gross, PhD, Chief Scientific Officer for…
